Sella, Tal
Zheng, Yue http://orcid.org/0000-0002-2294-813X
Rosenberg, Shoshana M.
Ruddy, Kathryn J. http://orcid.org/0000-0001-6298-332X
Gelber, Shari I.
Tamimi, Rulla M. http://orcid.org/0000-0003-2306-8668
Peppercorn, Jeffrey M.
Schapira, Lidia
Borges, Virginia F. http://orcid.org/0000-0003-1158-7524
Come, Steven E.
Carey, Lisa A. http://orcid.org/0000-0003-2388-4649
Winer, Eric P. http://orcid.org/0000-0002-8819-1723
Partridge, Ann H. http://orcid.org/0000-0002-4722-4824
Funding for this research was provided by:
Breast Cancer Research Foundation
Susan G. Komen
Article History
Received: 20 July 2022
Accepted: 30 March 2023
First Online: 25 April 2023
Competing interests
: TS received honorarium from Roche and travel expenses for Gilead. SMR reports research funding from Pfizer/Conquer Cancer. JMP reports institutional research funding from Outcomes4me, serving as a consultant for Abbott Labs and spousal employment by GlaxoSmithKline. LS reports serving as an advisor to Blue Note Therapeutics and Rubedo Life Sciences and serving as a consultant for Novartis. VFB reports institutional research funding from SeaGen, AstraZeneca, Olema, and Oncosec, serving as a consultant for SeaGen and AstraZeneca, and serving as founder/stock ownership in PerlaTx. LAC reports institutional research funding from Syndax, Novartis, NanoString Technologies, SeaGen, VeraCyte, and AstraZeneca. EPW served over the past 3 years as a consultant to and received honoraria from Carrick Therapeutics, Genentech/Roche, and Jounce Therapeutics. He is an uncompensated member of the Scientific Advisory Boards for Leap Therapeutics. AHP reports royalties for co-authoring the Breast Cancer Survivorship section of UpToDate. The remaining authors declare no competing interests.